 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
17 News |  |
- |||| GS-248 / Gesynta Pharma
Clinical: Ready for the First Time Disclosure of Clinical Candidate BI01029539 / GS-248, a mPGES1 Inhibitor @Boehringer #EFMCISMC22 (Twitter) - Sep 7, 2022
- ||| vipoglanstat (GS-248) / Gesynta Pharma
Trial completion: A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis (clinicaltrials.gov) - Aug 3, 2022
P2, N=69, Completed, Sponsor: Gesynta Pharma AB
Active, not recruiting --> Completed
- || vipoglanstat (GS-248) / Gesynta Pharma
Enrollment closed: A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis (clinicaltrials.gov) - Jun 16, 2022
P2, N=80, Active, not recruiting, Sponsor: Gesynta Pharma AB
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || vipoglanstat (GS-248) / Gesynta Pharma
Trial completion date, Trial primary completion date: A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis (clinicaltrials.gov) - Jan 28, 2022
P2, N=80, Recruiting, Sponsor: Gesynta Pharma AB
Recruiting --> Active, not recruiting Trial completion date: Feb 2022 --> Jun 2022 | Trial primary completion date: Feb 2022 --> Jun 2022
- | celecoxib oral / Generic mfg.
Preclinical, Journal: Inhibition of microsomal prostaglandin E synthase-1 ameliorates acute lung injury in mice. (Pubmed Central) - Aug 21, 2021
Trial completion date: Feb 2022 --> Jun 2022 | Trial primary completion date: Feb 2022 --> Jun 2022 BI 1029539 ameliorates leukocyte infiltration and lung injury resulting from both endotoxin-induced and sepsis-induced lung injury.
- || vipoglanstat (GS-248) / Gesynta Pharma
Trial completion date, Trial primary completion date: A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis (clinicaltrials.gov) - Aug 18, 2021
P2, N=80, Recruiting, Sponsor: Gesynta Pharma AB
BI 1029539 ameliorates leukocyte infiltration and lung injury resulting from both endotoxin-induced and sepsis-induced lung injury. Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021
- || GS-248 / Gesynta Pharma
Gesynta Pharma rapporterar betydande framsteg i utvecklingsprogrammet för läkemedelskandidaten GS-248 https://t.co/i8L8RCaYAS (Twitter) - Jun 13, 2021
- |||| vipoglanstat (GS-248) / Gesynta Pharma
New P2 trial: A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis (clinicaltrials.gov) - Feb 7, 2021
P2, N=80, Recruiting, Sponsor: Gesynta Pharma AB
- |||| GS-248 / Gesynta Pharma
Clinical: Gesynta Pharma inleder fas II-studie med sin läkemedelskandidat GS-248 i patienter med systemisk skleros https://t.co/sOM4px0Fmu (Twitter) - Jan 25, 2021
- || vipoglanstat (GS-248) / Gesynta Pharma
New P1 trial: A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248 (clinicaltrials.gov) - Nov 4, 2020
P1, N=14, Completed, Sponsor: Gesynta Pharma AB
- ||| vipoglanstat (GS-248) / Gesynta Pharma
Trial completion, Trial completion date, Trial primary completion date: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248 (clinicaltrials.gov) - Sep 2, 2020
P1, N=72, Completed, Sponsor: Gesynta Pharma AB
Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021 Recruiting --> Completed | Trial completion date: Jun 2020 --> Dec 2019 | Trial primary completion date: Jun 2020 --> Dec 2019
- | OX-MPI / Gesynta
Journal: Inhibition of human microsomal PGE2 synthase-1 reduces seizure-induced increases of P-glycoprotein expression and activity at the blood-brain barrier. (Pubmed Central) - Jun 9, 2020
We show that BI1029539, an mPGES-1 inhibitor, prevented up-regulation of P-gp expression and transport activity in capillaries exposed to glutamate and in capillaries from humanized mPGES-1 mice after SE. Our data provide key signaling steps underlying seizure-induced P-gp up-regulation and suggest that mPGES-1 inhibitors could potentially prevent P-gp up-regulation in epilepsy.-Soldner, E. L. B., Hartz, A. M. S., Akanuma, S.-I., Pekcec, A., Doods, H., Kryscio, R. J., Hosoya, K.-I., Bauer, B. Inhibition of human microsomal PGE2 synthase-1 reduces seizure-induced increases of P-glycoprotein expression and activity at the blood-brain barrier.
- OX-MPI / Gesynta
[VIRTUAL] INHIBITION OF MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES-1) BY GS-248 REDUCES PROSTAGLANDIN E2 BIOSYNTHESIS WHILE INCREASING PROSTACYCLIN IN HUMAN SUBJECTS (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_3406;
There was a sustained inhibition of LPS induced PGE 2 formation in whole blood. In urine, there was a metabolite shift showing reduced PGE 2 and increased PGI 2 , while celecoxib reduced both PGE 2 and PGI 2 metabolites.
- | vipoglanstat (GS-248) / Gesynta Pharma
New P1 trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248 (clinicaltrials.gov) - Jul 28, 2019
P1, N=80, Recruiting, Sponsor: Gesynta Pharma AB